<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) screening is most commonly performed in the United States using an opportunistic approach: patients coming to a physician's office for other unrelated reasons are offered screening with either fecal occult blood tests or, more commonly, a referral for colonoscopy </plain></SENT>
<SENT sid="1" pm="."><plain>This approach has been effective to a point </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening rates are increasing, but are still suboptimal and vary across different regions of the United States </plain></SENT>
<SENT sid="3" pm="."><plain>Mailed fecal immunochemical test (FIT) outreach has the potential to allow more consistent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening, by moving beyond opportunistic, office visit-based screening, to an organized approach </plain></SENT>
<SENT sid="4" pm="."><plain>The study by van Roon et al. in this issue of the American Journal of Gastroenterology demonstrates that mailing FIT collection devices will not result in decreased sensitivity for 10-14 days following the specimen collection </plain></SENT>
</text></document>